ClinicalTrials.gg
CompletedNCT04949490Updated Sep 19, 2024Results posted

A Trial Investigating the Safety and Effects of One or Two Additional Doses of Comirnaty or One Dose of BNT162b2s01 in BNT162-01 or BNT162-04 Trial Subjects

A Phase 2 interventional study of BNT162b2s01 and BNT162b2 in COVID-19 and SARS-CoV-2 Infection, sponsored by BioNTech SE. Completed at 4 sites in Germany. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-09-19.

Sponsored by BioNTech SE · Phase 2, Interventional, and Prevention

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
137
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 54 studies testing BNT162 Vaccine in COVID-19 — 4 open to participants now, 6 under way, 1 of them phase 3. BNT162 Vaccine · COVID-19.

Enrollment
43rd of 54
137 · median 575
Started
2021
with 29 others
Phase 2
16 of 54
1 open now
Registered
19th of 54
by date
Lead sponsor
20 of 54
BioNTech SE

Among the 54 studies testing BNT162 Vaccine in COVID-19, this one is the 43rd largest by enrollment, is one of 30 that started in 2021, is one of 16 in phase 2, and was the 19th registered.

COVID-19

7,994 studies on the registry are indexed under COVID-19; 468 are open to participants now.

Browse COVID-19 studies →

Open to participants now

4 of the 54 studies testing BNT162 Vaccine in COVID-19 are open now, in 6 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

About BNT162 Vaccine

No approval found in the FDA or EMA files read. How studies give it is on its page →

Who these studies take

Of the 356 COVID-19 studies recruiting now, 206 (58%) set no upper age limit and 83 (23%) stop at 75 or younger; 91 take children under 18; 135 take healthy volunteers.

This study: 18 Years and older · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 54 studies testing BNT162 Vaccine in COVID-19, or all of them as a file.
02

Study summary

Trial to evaluate the safety and immunogenicity of one or two boosting doses of Comirnaty or one dose of BNT162b2s01 (Variant of concern [VOC] strain B.1.351) in BNT162-01 trial participants, or two boosting doses of Comirnaty in BNT162-04 trial participants.

Trial participants from BNT162-01 who received two injections of 30 μg Comirnaty were randomized 2:1 to one booster injection (BNT162b2s01: Comirnaty). Trial participants in either the trial BNT162-01 or BNT162-04 who did not receive the full two vaccinations of 30 μg Comirnaty were offered two injections of 30 μg Comirnaty as per the conditional marketing authorization. All potential rollover volunteers must enroll in this trial within less than 18 months of their last injection of a BNT162 candidate vaccine in the parent BNT162-01 or BNT162-04 trials.

Read the detailed description

Group A trial participants were randomized 2:1 to BNT162b2s01:Comirnaty. Group B trial participants were allocated to trial treatment without active randomization and selected participants were asked to participate in the detailed immunogenicity assessment based on their parent trial cohort.

03

Conditions studied

  • COVID-19
  • SARS-CoV-2 Infection

Keywords

  • Infections, Respiratory
  • Virus Diseases
  • Infection Viral
  • Vaccine Adverse Reaction
  • RNA Virus Infections
  • Protection Against COVID-19 and Infections With SARS-CoV-2
  • Prevention of COVID-19 disease
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Had given by signing the informed consent form (ICF) before initiation of any trial-specific procedures.
  • Were willing and able to comply with scheduled visits, treatment schedule, laboratory tests, lifestyle restrictions (including those requested by the German and federal Governments, e.g., to follow good practices to reduce chances of spreading COVID 19), and other requirements of the trial.
  • Have received BNT162 vaccine candidates in the BNT162-01 or BNT162-04 trials.
  • Remained overall healthy (i.e., has not medically deteriorated significantly since participation in the parent trial, is not anticipated to die in the next 26 weeks, and is able to provide blood as specified by the trial without anticipated, deleterious medical consequences) in the clinical judgment of the investigator based on medical history and physical examination. Screening clinical laboratory tests are to assess the participants' "new baseline" unless required for eligibility. Note: in particular, caution should be used with a subject who has a history of cardiovascular disease, e.g., myocarditis, pericarditis, myocardial infarction, congestive heart failure, cardiomyopathy, or arrhythmia.
  • Agreed not to enroll in another trial of an IMP, starting after Visit 0 and continuously until Visit 5 (Day 50).
  • Less than 18 months have passed since their last IMP injection in their parent trial.
  • If they received 30 μg Comirnaty twice in the BNT162-01 trial, Visit 1 in this trial is ≥24 weeks after their last IMP injection, unless the subject is a Cohort 13 transplant subject of the BNT162-01 trial.
  • If they received any other BNT162 vaccine candidate than Comirnaty in the BNT162-01 or BNT162-04 trial or are a Cohort 13 transplant subject, Visit 1 in this trial is ≥12 weeks after their last IMP injection.
  • Have not been diagnosed with SARS-CoV-2 infection in the 12 weeks prior to day 1 (baseline). Participants who screen-fail on this criterion may be rescreened.

Exclusion criteria

Exclusion Criteria:

  • Have received any SARS-CoV-2 vaccine outside of the BNT162-01 or BNT162-04 trials.
  • Have had a known allergy, , or intolerance to the planned IMP including any of the IMP.
  • Have had a current febrile illness (body temperature ≥38.0°C) or other acute illness within 48 hours prior to day 1/IMP injection in this trial. Participants who screen-fail on this criterion may be rescreened.
  • Have received a live or within 30 days prior to day 1/IMP injection, or any other vaccination within 14 days prior to day 1/IMP injection. Participants who screen-fail on this criterion may be rescreened.
  • Have had an ongoing AE assessed as related to any BNT162-01 or BNT162-04 trial vaccine.
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

05

Study design

Phase
Phase 2
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
137 participants (actual)

Study arms

  • Experimental
    Group A, BNT162b2s01 30 μg (1 dose)

    Trial participants from BNT162-01 (excluding transplant participants from Cohort 13) who received two injections of 30 μg BNT162b2 (Comirnaty) in the parent trial received one booster injection of BNT162b2s01 on Day 1. Day 1 (baseline in this trial) must have occurred ≥24 weeks after the last BNT162b2 (Comirnaty) injection in the parent BNT162-01 trial.

    Biological: BNT162b2s01

  • Experimental
    Group A, BNT162b2 30 μg (1 dose)

    Trial participants from BNT162-01 (excluding transplant participants from Cohort 13) who received two injections of 30 μg BNT162b2 (Comirnaty) in the parent trial received one booster injection of BNT162b2 (Comirnaty) on Day 1. Day 1 (baseline in this trial) must have occurred ≥24 weeks after the last BNT162b2 (Comirnaty) injection in the parent BNT162-01 trial.

    Biological: BNT162b2

  • Experimental
    Group B, BNT162b2 30 μg (2 doses)

    Trial participants in either the trial BNT162-01 (excluding transplant participants from Cohort 13) or BNT162-04 who did not receive the full two vaccinations of 30 μg BNT162b2 (Comirnaty) in the respective parent trial were offered two injections of 30 μg BNT162b2 (Comirnaty) as per the conditional marketing authorization on Day 1 and Day 21. Day 1 (baseline in this trial) must have occurred ≥12 weeks after receiving the last BNT162 candidate vaccine in the respective parent BNT162-01 or BNT162-04 trial.

    Biological: BNT162b2

  • Experimental
    Group B transplant subjects, BNT162b2 30 μg (2 doses)

    Transplant trial participants from Cohort 13 of the trial BNT162-01 received one injection of 30 μg BNT162b2 (Comirnaty) on Day 1 which was followed 3 to 7 months afterward by a second injection of BNT162b2 (Comirnaty). Day 1 (baseline in this trial) must have occurred ≥12 weeks after receiving the last BNT162 candidate vaccine in the parent BNT162-01 trial.

    Biological: BNT162b2

Interventions

  • BiologicalBNT162b2s01

    intramuscular (IM) injection

  • BiologicalBNT162b2

    IM injection

    Also known as: Comirnaty

06

What researchers measure

Primary outcomes

  1. The Number and Percentage of Participants in Each Treatment Group With at Least One Serious Adverse Event (SAE) or Adverse Events of Special Interest (AESIs)

    For treatment-emergent SAEs and AESIs (TESAEs, TEAESIs), the data refers to the interval "Dose 1 up to 28 days after Dose 1". For other SAEs and AESIs, the data refers to the interval "Dose 1 up to 26 weeks after Dose 1". A TESAE/TEAESI is defined as any SAE/AESI with an onset after the first IMP dose or worsened after the first IMP dose (if the SAE/AESI was present before the first administration of IMP). SAEs/AESIs with an onset date more than 28 days after the last administration of IMP will be considered as TESAE/TEAESI only if assessed as related to IMP by the investigator. Participants of the Group B immunology subset are also included in the respective Group B arms and therefore counted in more than one arm/group. Overall a total of 137 participants were enrolled into this study (including the Group B immunology subset participants).

    Time frame: Up to 26 weeks after the first IMP injection

  2. The Number and Percentage of Participants With Solicited Local Reactions at the Injection Site Recorded up to 7 Days After Each IMP Injection for Group A and for a Selected Subset (Immunology Subset) of Group B Participants.

    Local reactions (pain, tenderness, erythema/redness, induration/swelling) were graded using criteria based on the guidance given in US FDA Guidance for Industry "Toxicity Grading Scale for Healthy Adult and Adolescent Volunteers Enrolled in Preventive Vaccine Clinical Trials"; the guidance uses the Grades 1 (mild), 2 (moderate), 3 (severe), and 4 (potentially life-threatening). The reporting of local reactions was based on the participant's assessments via daily solicited reports in the participant diaries. Participants of the Group B immunology subset are part of the Group B. The 'Total' arms include all participants from the respective Group A and Group B immunology subset arms presented.

    Time frame: Group A: From Day 1 to Day 8; For Group B (except transplant participants): From Day 1 to Day 8 for Dose 1, and from Day 22 to Day 29 for Dose 2. For Group B transplant participants: From Day 1 to Day 8 for Dose 1, and up to 7 days after Dose 2.

  3. The Number and Percentage of Participants With Solicited Systemic Reactions Recorded up to 7 Days After Each IMP Injection for Group A and for a Selected Subset (Immunology Subset) of Group B Participants.

    Systemic reactions (nausea, vomiting, diarrhea, headache, fatigue, myalgia, arthralgia, chills and fever) were graded using criteria based on the guidance given in US FDA Guidance for Industry "Toxicity Grading Scale for Healthy Adult and Adolescent Volunteers Enrolled in Preventive Vaccine Clinical Trials"; the guidance uses the Grades 1 (mild), 2 (moderate), 3 (severe), and 4 (potentially life-threatening). The reporting of systemic reactions was based on the participant's assessments via daily solicited reports in the participant diaries. Participants of the Group B immunology subset are part of the Group B. The 'Total' arms include all participants from the respective Group A and Group B immunology subset arms presented.

    Time frame: Group A: From Day 1 to Day 8; For Group B (except transplant participants): From Day 1 to Day 8 for Dose 1, and from Day 22 to Day 29 for Dose 2. For Group B transplant participants: From Day 1 to Day 8 for Dose 1, and up to 7 days after Dose 2.

  4. The Number and Percentage of Participants With at Least One Unsolicited TEAE Occurring up to 28 Days After IMP Injection in Each Treatment Group for Group A and for a Selected Subset (Immunology Subset) of Group B Participants

    A TEAE is defined as any AE with an onset after the first IMP injection or worsened after the first IMP injection (if the AE was present before the first administration of IMP). AEs with an onset date more than 28 days after the last administration of IMP will be considered as treatment-emergent only if assessed as related to IMP by the investigator. Participants of the Group B immunology subset are part of the Group B. The 'Total' arms include all participants from the respective Group A and Group B immunology subset arms presented.

    Time frame: Group A: Up to 28 days after Dose 1. Group B: Up to 28 days after Dose 1 and up to 28 days after Dose 2.

Secondary outcomes

  1. Neutralizing Antibody Titers From Reference Strain and SARS-CoV-2 Variant B.1.351

    For Group A participants and Group B participants (except transplant subjects). Non-transplant participants of the Group B immunology subset are also part of the respective Group B arm and therefore occurring in more than one arm/group. The 'Total' arm for Group A include all participants from the Group A arms/groups.

    Time frame: Group A: At baseline (Day 1) and Day 8 and at Week 4 Day 29), Week 12 (Day 85), and Week 26 (Day 182). Group B: At baseline (Day 1) and Day 8 and at Week 3 (Day 22), Week 4 (Day 29), Week 7 (Day 50), Week 12 (Day 85), and Week 26 (Day 182).

  2. Antibody Titers (ELISA) to Recombinant S1 and RBD Protein Derived From Reference and SARS-CoV-2 Variant B.1.351

    For Group A participants and Group B participants (except transplant subjects). Non-transplant participants in the Group B immunology subset arm are also part of the respective Group B arm and therefore occurring in more than one arm/group. The 'Total' arm for Group A include all participants from the Group A arms/groups.

    Time frame: Group A: At baseline (Day 1) and Day 8 and at Week 4 Day 29), Week 12 (Day 85), and Week 26 (Day 182). Group B: At baseline (Day 1) and Day 8 and at Week 3 (Day 22), Week 4 (Day 29), Week 7 (Day 50), Week 12 (Day 85), and Week 26 (Day 182).

  3. SARS-CoV-2 Functional Cross-neutralization (GMT Ratios) of Variant B.1.351 to Reference Strain

    For Group A only. The geometric mean titer (GMT) ratio is calculated as the GMT of reference divided by the GMT of variant B.1.351. The 'Total' arm for Group A include all participants from the two Group A arms/groups.

    Time frame: Up to 26 weeks after the first IMP injection (Dose 1)

  4. Neutralizing Antibody Titers (Reference Strain) Derived From SARS-CoV-2

    For Group B transplant subjects, assessed at baseline (Day 1 of Dose 1) and then Day 8, Weeks 4, 12, and 26 post Dose 1, and at Dose 2 (Day 1) and the Day 8, Weeks 4, 12, and 26 post Dose 2. Because the 11 participants of the arm 'Group B Immunology Subset Transplant Participants' are the same 11 participants of the arm 'Group B Immunology Subset Transplant Participants', data is not presented for this arm to avoid duplication of data.

    Time frame: From baseline (Day 1 of Dose 1) up to 26 weeks after Dose 2

  5. Antibody Titers (ELISA) (Reference Strain) to Recombinant S1 and RBD Protein Derived From SARS-CoV-2

    For Group B transplant subjects, assessed at baseline (Day 1 of Dose 1) and then Day 8, Weeks 4, 12, and 26 post Dose 1, and at Dose 2 (Day 1) and the Day 8, Weeks 4, 12, and 26 post Dose 2. Because the 11 participants of the arm 'Group B Immunology Subset Transplant Participants' are the same 11 participants of the arm 'Group B Immunology Subset Transplant Participants', data is not presented for this arm to avoid duplication of data.

    Time frame: From baseline (Day 1 of Dose 1) up to 26 weeks after Dose 2

07

Results

Posted Sep 19, 2024

Participant flow

This rollover study (BNT162-14) has enrolled BNT162-01 (NCT04380701) or BNT162-04 (NCT04537949) study participants meeting all inclusion/exclusion criteria defined in the study protocol. The first participant was enrolled on 26 JUL 2021. The last visit of the last participant was on 16 SEP 2022.

Group A and Group B
Participant flow — Group A and Group B
MilestoneGroup A ComirnatyGroup A BNT162b2s01Group B Non-transplant ParticipantsGroup B Transplant ParticipantsGroup B Immunology Subset Non-transplant ParticipantsGroup B Immunology Subset Transplant Participants
Started2144611100
Completed214460900
Not completed001200
Withdrew: Non-study sars-cov-2 vaccination000200
Withdrew: Withdrawal by subject001000
Subset Group B Immunogenicity Evaluation
Participant flow — Subset Group B Immunogenicity Evaluation
MilestoneGroup A ComirnatyGroup A BNT162b2s01Group B Non-transplant ParticipantsGroup B Transplant ParticipantsGroup B Immunology Subset Non-transplant ParticipantsGroup B Immunology Subset Transplant Participants
Started00002211
Completed0000219
Not completed000012
Withdrew: Non-study sars-cov-2 vaccination000002
Withdrew: Withdrawal by subject000010

Outcome measures

PrimaryThe Number and Percentage of Participants in Each Treatment Group With at Least One Serious Adverse Event (SAE) or Adverse Events of Special Interest (AESIs)

For treatment-emergent SAEs and AESIs (TESAEs, TEAESIs), the data refers to the interval "Dose 1 up to 28 days after Dose 1". For other SAEs and AESIs, the data refers to the interval "Dose 1 up to 26 weeks after Dose 1". A TESAE/TEAESI is defined as any SAE/AESI with an onset after the first IMP dose or worsened after the first IMP dose (if the SAE/AESI was present before the first administration of IMP). SAEs/AESIs with an onset date more than 28 days after the last administration of IMP will be considered as TESAE/TEAESI only if assessed as related to IMP by the investigator. Participants of the Group B immunology subset are also included in the respective Group B arms and therefore counted in more than one arm/group. Overall a total of 137 participants were enrolled into this study (including the Group B immunology subset participants).

Time frame:
Up to 26 weeks after the first IMP injection
Reported as:
Count of participants · Participants
The Number and Percentage of Participants in Each Treatment Group With at Least One Serious Adverse Event (SAE) or Adverse Events of Special Interest (AESIs)
ParticipantsGroup A ComirnatyGroup A BNT162b2s01Group A TotalGroup B Non-transplant ParticipantsGroup B Transplant ParticipantsGroup B TotalGroup B Immunology Subset Non-transplant ParticipantsGroup B Immunology Subset Transplant ParticipantsGroup B Immunology Subset Total
Any SAE022145044
Any related SAE000000000
Any TESAE011011000
Any related TESAE000000000
Any AESI000000000
Any related AESI000000000
Any TEAESI000000000
PrimaryThe Number and Percentage of Participants With Solicited Local Reactions at the Injection Site Recorded up to 7 Days After Each IMP Injection for Group A and for a Selected Subset (Immunology Subset) of Group B Participants.

Local reactions (pain, tenderness, erythema/redness, induration/swelling) were graded using criteria based on the guidance given in US FDA Guidance for Industry "Toxicity Grading Scale for Healthy Adult and Adolescent Volunteers Enrolled in Preventive Vaccine Clinical Trials"; the guidance uses the Grades 1 (mild), 2 (moderate), 3 (severe), and 4 (potentially life-threatening). The reporting of local reactions was based on the participant's assessments via daily solicited reports in the participant diaries. Participants of the Group B immunology subset are part of the Group B. The 'Total' arms include all participants from the respective Group A and Group B immunology subset arms presented.

Time frame:
Group A: From Day 1 to Day 8; For Group B (except transplant participants): From Day 1 to Day 8 for Dose 1, and from Day 22 to Day 29 for Dose 2. For Group B transplant participants: From Day 1 to Day 8 for Dose 1, and up to 7 days after Dose 2.
Reported as:
Count of participants · Participants
The Number and Percentage of Participants With Solicited Local Reactions at the Injection Site Recorded up to 7 Days After Each IMP Injection for Group A and for a Selected Subset (Immunology Subset) of Group B Participants.
ParticipantsGroup A ComirnatyGroup A BNT162b2s01Group A TotalGroup B Immunology Subset Non-transplant ParticipantsGroup B Immunology Subset Transplant ParticipantsGroup B Immunology Subset Total
Dose 1 up to 7 days after Dose 1: Number of participants with any local reaction204161211031
Dose 1 up to 7 days after Dose 1: Number of participants with any grade >= 3 local reaction123314
Dose 2 up to 7 days after Dose 2: Number of participants with any local reaction———20525
Dose 2 up to 7 days after Dose 2: Number of participants with any grade >= 3 local reaction———404
PrimaryThe Number and Percentage of Participants With Solicited Systemic Reactions Recorded up to 7 Days After Each IMP Injection for Group A and for a Selected Subset (Immunology Subset) of Group B Participants.

Systemic reactions (nausea, vomiting, diarrhea, headache, fatigue, myalgia, arthralgia, chills and fever) were graded using criteria based on the guidance given in US FDA Guidance for Industry "Toxicity Grading Scale for Healthy Adult and Adolescent Volunteers Enrolled in Preventive Vaccine Clinical Trials"; the guidance uses the Grades 1 (mild), 2 (moderate), 3 (severe), and 4 (potentially life-threatening). The reporting of systemic reactions was based on the participant's assessments via daily solicited reports in the participant diaries. Participants of the Group B immunology subset are part of the Group B. The 'Total' arms include all participants from the respective Group A and Group B immunology subset arms presented.

Time frame:
Group A: From Day 1 to Day 8; For Group B (except transplant participants): From Day 1 to Day 8 for Dose 1, and from Day 22 to Day 29 for Dose 2. For Group B transplant participants: From Day 1 to Day 8 for Dose 1, and up to 7 days after Dose 2.
Reported as:
Count of participants · Participants
The Number and Percentage of Participants With Solicited Systemic Reactions Recorded up to 7 Days After Each IMP Injection for Group A and for a Selected Subset (Immunology Subset) of Group B Participants.
ParticipantsGroup A ComirnatyGroup A BNT162b2s01Group A TotalGroup B Immunology Subset Non-transplant ParticipantsGroup B Immunology Subset Transplant ParticipantsGroup B Immunology Subset Total
Dose 1 up to 7 days after Dose 1: Number of participants with any systemic reaction18335120828
Dose 1 up to 7 days after Dose 1: Number of participants with any grade >= 3 systemic reaction4913202
Dose 2 up to 7 days after Dose 2: Number of participants with any systemic reaction———17421
Dose 2 up to 7 days after Dose 2: Number of participants with any grade >= 3 systemic reaction———707
PrimaryThe Number and Percentage of Participants With at Least One Unsolicited TEAE Occurring up to 28 Days After IMP Injection in Each Treatment Group for Group A and for a Selected Subset (Immunology Subset) of Group B Participants

A TEAE is defined as any AE with an onset after the first IMP injection or worsened after the first IMP injection (if the AE was present before the first administration of IMP). AEs with an onset date more than 28 days after the last administration of IMP will be considered as treatment-emergent only if assessed as related to IMP by the investigator. Participants of the Group B immunology subset are part of the Group B. The 'Total' arms include all participants from the respective Group A and Group B immunology subset arms presented.

Time frame:
Group A: Up to 28 days after Dose 1. Group B: Up to 28 days after Dose 1 and up to 28 days after Dose 2.
Reported as:
Count of participants · Participants
The Number and Percentage of Participants With at Least One Unsolicited TEAE Occurring up to 28 Days After IMP Injection in Each Treatment Group for Group A and for a Selected Subset (Immunology Subset) of Group B Participants
ParticipantsGroup A ComirnatyGroup A BNT162b2s01Group A TotalGroup B Immunology Subset Non-transplant ParticipantsGroup B Immunology Subset Transplant ParticipantsGroup B Immunology Subset Total
Dose 1 up to 28 days after Dose 1: Number of participants with any TEAE814225611
Dose 1 up to 28 days after Dose 1: Number of participants with any grade >=3 TEAE112000
Dose 2 up to 28 days after Dose 2; Number of participants with any TEAE———527
Dose 2 up to 28 days after Dose 2; Number of participants with any grade >=3 TEAE———000
SecondaryNeutralizing Antibody Titers From Reference Strain and SARS-CoV-2 Variant B.1.351

For Group A participants and Group B participants (except transplant subjects). Non-transplant participants of the Group B immunology subset are also part of the respective Group B arm and therefore occurring in more than one arm/group. The 'Total' arm for Group A include all participants from the Group A arms/groups.

Time frame:
Group A: At baseline (Day 1) and Day 8 and at Week 4 Day 29), Week 12 (Day 85), and Week 26 (Day 182). Group B: At baseline (Day 1) and Day 8 and at Week 3 (Day 22), Week 4 (Day 29), Week 7 (Day 50), Week 12 (Day 85), and Week 26 (Day 182).
Reported as:
Geometric mean · Titer
Neutralizing Antibody Titers From Reference Strain and SARS-CoV-2 Variant B.1.351
TiterGroup A ComirnatyGroup A BNT162b2s01Group A TotalGroup B Non-transplant ParticipantsGroup B Immunology Subset Non-transplant Participants
Response neutralizing antibody titers reference strain - Baseline (Day 1)21.4 (13.2 to 34.5)21.3 (15.3 to 29.6)21.3 (16.4 to 27.7)15.6 (11.5 to 21.0)13.3 (8.3 to 21.3)
Response neutralizing antibody titers variant B.1.351 - Baseline (Day1)NA (NA to NA)NA (NA to NA)NA (NA to NA)——
Response neutralizing antibody titers reference strain - Day 8640.0 (376.6 to 1087.7)349.0 (254.5 to 478.6)424.5 (322.5 to 558.8)729.3 (485.4 to 1095.8)1093.4 (719.8 to 1661.0)
Response neutralizing antibody titers variant B.1.351 - Day 8285.1 (164.2 to 495.0)330.2 (232.3 to 469.5)314.9 (235.8 to 420.6)——
Response neutralizing antibody titers reference strain - Week 3 (Day 22)———1085.6 (775.5 to 1519.5)1183.0 (738.2 to 1896.0)
Response neutralizing antibody titers reference strain - Week 4 (Day 29)570.2 (309.3 to 1051.1)509.3 (372.4 to 696.6)528.2 (399.1 to 699.2)1789.7 (1367.3 to 2342.6)1868.1 (1278.7 to 2729.3)
Response neutralizing antibody titers variant B.1.351 - Week 4 (Day 29)271.3 (157.9 to 466.1)325.1 (233.2 to 453.3)306.6 (232.4 to 404.6)——
Response neutralizing antibody titers reference strain - Week 7———1386.0 (1054.5 to 1821.6)1429.2 (864.5 to 2362.8)
Response neutralizing antibody titers reference strain - Week 12 (Day 85)371.2 (202.5 to 680.5)282.1 (181.0 to 439.8)313.9 (221.5 to 444.9)1348.3 (992.8 to 1831.1)1301.3 (795.2 to 2129.5)
Response neutralizing antibody titers variant B.1.351 - Week 12 (Day 85)122.9 (65.3 to 231.4)259.4 (162.6 to 413.7)194.0 (133.0 to 282.9)——
Response neutralizing antibody titers reference strain - Week 26 (Day 182)336.2 (159.6 to 708.6)132.0 (64.6 to 269.7)218.4 (130.0 to 366.8)659.8 (469.5 to 927.1)710.1 (439.5 to 1147.3)
Response neutralizing antibody titers variant B.1.351 - Week 26 (Day 182)140.2 (60.4 to 325.2)129.5 (63.8 to 262.6)135.1 (79.3 to 230.3)——
SecondaryAntibody Titers (ELISA) to Recombinant S1 and RBD Protein Derived From Reference and SARS-CoV-2 Variant B.1.351

For Group A participants and Group B participants (except transplant subjects). Non-transplant participants in the Group B immunology subset arm are also part of the respective Group B arm and therefore occurring in more than one arm/group. The 'Total' arm for Group A include all participants from the Group A arms/groups.

Time frame:
Group A: At baseline (Day 1) and Day 8 and at Week 4 Day 29), Week 12 (Day 85), and Week 26 (Day 182). Group B: At baseline (Day 1) and Day 8 and at Week 3 (Day 22), Week 4 (Day 29), Week 7 (Day 50), Week 12 (Day 85), and Week 26 (Day 182).
Reported as:
Geometric mean · Titer
Antibody Titers (ELISA) to Recombinant S1 and RBD Protein Derived From Reference and SARS-CoV-2 Variant B.1.351
TiterGroup A ComirnatyGroup A BNT162b2s01Group A TotalGroup B Non-transplant ParticipantsGroup B Immunology Subset Non-transplant Participants
Response antibody titers IgG RBD Domain reference strain (ELISA) - Baseline (Day1)2216.1 (1507.6 to 3257.7)2161.4 (1634.7 to 2857.8)2178.9 (1748.0 to 2716.1)2135.4 (1303.7 to 3497.5)2056.4 (1297.3 to 3259.6)
Response antibody titers IgG RBD Domain variant B.1.351 (ELISA) - Baseline (Day 1)566.5 (370.9 to 865.3)588.7 (438.4 to 790.6)581.5 (459.5 to 735.8)——
Response antibody titers IgG S Protein reference strain (ELISA) - Baseline (Day 1)3209.0 (2045.6 to 5033.9)2594.7 (1977.5 to 3404.4)2779.1 (2210.9 to 3493.2)1634.4 (1025.5 to 2605.0)1636.2 (885.2 to 3024.5)
Response antibody titers IgG S Protein variant B.1.351 (ELISA) - Baseline (Day 1)7164.8 (4231.7 to 12130.9)9267.9 (6837.3 to 12562.5)8528.4 (6572.5 to 11066.5)——
Response antibody titers IgG RBD Domain reference strain (ELISA) - Day 8NA (NA to NA)48945.7 (35518.9 to 67447.9)NA (NA to NA)48805.7 (29759.0 to 80043.1)NA (NA to NA)
Response antibody titers IgG RBD Domain variant B.1.351 (ELISA) - Day 822903.0 (11936.4 to 43945.2)21244.0 (15712.2 to 28723.3)21766.4 (16403.7 to 28882.2)——
Response antibody titers IgG S Protein reference strain (ELISA) - Day 8NA (NA to NA)NA (NA to NA)NA (NA to NA)45270.4 (27269.8 to 75153.2)NA (NA to NA)
Response antibody titers IgG S Protein variant B.1.351 (ELISA) - Day 8520744.5 (258322.6 to 1049752.6)480042.7 (319790.9 to 720599.2)492832.1 (348924.0 to 696092.7)——
Response antibody titers IgG RBD Domain reference strain (ELISA) - Week 3———NA (NA to NA)NA (NA to NA)
Response antibody titers IgG S Protein reference strain (ELISA) - Week 3———NA (NA to NA)NA (NA to NA)
Response antibody titers IgG RBD Domain reference strain (ELISA) - Week 4NA (NA to NA)NA (NA to NA)NA (NA to NA)NA (NA to NA)NA (NA to NA)
Response antibody titers IgG RBD Domain variant B.1.351 (ELISA) - Week 418959.7 (11062.8 to 32493.5)21082.1 (16052.9 to 27686.8)20371.6 (15940.0 to 26035.3)——
Response antibody titers IgG S Protein reference strain (ELISA) - Week 4NA (NA to NA)NA (NA to NA)NA (NA to NA)NA (NA to NA)NA (NA to NA)
Response antibody titers IgG S Protein variant B.1.351 (ELISA) - Week 4394493.5 (198914.7 to 782371.2)362296.9 (259569.0 to 505680.9)372400.7 (274455.6 to 505299.6)——
Response antibody titers IgG RBD Domain reference strain (ELISA) - Week 7———NA (NA to NA)NA (NA to NA)
Response antibody titers IgG S Protein reference strain (ELISA) - Week 7———NA (NA to NA)NA (NA to NA)
Response antibody titers IgG RBD Domain reference strain (ELISA) - Week 1223883.9 (15193.4 to 37545.2)28535.3 (20676.5 to 39381.0)26627.5 (20616.5 to 34391.0)NA (NA to NA)NA (NA to NA)
Response antibody titers IgG RBD Domain variant B.1.351 (ELISA) - Week 1211106.8 (6446.7 to 19135.5)14367.3 (9798.4 to 21066.5)12998.8 (9570.3 to 17655.4)——
Response antibody titers IgG S Protein reference strain (ELISA) - Week 1250709.2 (33710.6 to 76279.3)NA (NA to NA)NA (NA to NA)NA (NA to NA)NA (NA to NA)
Response antibody titers IgG S Protein variant B.1.351 (ELISA) - Week 12178167.5 (95710.4 to 331663.8)305041.0 (196223.1 to 474205.2)247480.6 (173229.4 to 353558.0)——
Response antibody titers IgG RBD Domain reference strain (ELISA) - Week 2614309.8 (7900.1 to 25920.0)8670.5 (5238.9 to 14349.9)11355.5 (7717.3 to 16709.0)34032.7 (25327.8 to 45729.3)38865.2 (23611.8 to 63972.6)
Response antibody titers IgG RBD Domain variant B.1.351 (ELISA) - Week 269829.9 (4948.4 to 19526.7)6967.7 (4124.5 to 11770.9)8386.3 (5479.1 to 12835.9)——
Response antibody titers IgG S Protein reference strain (ELISA) - Week 2627732.0 (15894.6 to 48385.3)17049.8 (10185.6 to 28539.8)22155.2 (15250.2 to 32186.6)NA (NA to NA)NA (NA to NA)
Response antibody titers IgG S Protein variant B.1.351 (ELISA) - Week 26142683.7 (67849.2 to 300057.1)91825.4 (50843.9 to 165838.9)116420.8 (72901.4 to 185919.5)——
SecondarySARS-CoV-2 Functional Cross-neutralization (GMT Ratios) of Variant B.1.351 to Reference Strain

For Group A only. The geometric mean titer (GMT) ratio is calculated as the GMT of reference divided by the GMT of variant B.1.351. The 'Total' arm for Group A include all participants from the two Group A arms/groups.

Time frame:
Up to 26 weeks after the first IMP injection (Dose 1)
Reported as:
Number · GMT ratio
SARS-CoV-2 Functional Cross-neutralization (GMT Ratios) of Variant B.1.351 to Reference Strain
GMT ratioGroup A ComirnatyGroup A BNT162b2s01Group A Total
Day 1 - Response neutralizing antibody titers - GMT ratio3.13.03.0
Day 1 - Response antibody titers IgG RBD Domain - GMT ratio3.93.73.7
Day 1 - Response antibody titers IgG S Protein - GMT ratio0.40.30.3
Day 8 - Response neutralizing antibody titers - GMT ratio2.21.11.3
Day 8 - Response antibody titers IgG RBD Domain - GMT ratio2.92.32.5
Day 8 - Response antibody titers IgG S Protein - GMT ratio0.20.20.2
Week 4 (Day 29) - Response neutralizing antibody titers - GMT ratio2.11.61.7
Week 4 (Day 29) - Response antibody titers IgG RBD Domain - GMT ratio3.12.62.8
Week 4 (Day 29) - Response antibody titers IgG S Protein - GMT ratio0.20.20.2
Week 12 (Day 85) - Response neutralizing antibody titers - GMT ratio3.01.11.6
Week 12 (Day 85) - Response antibody titers IgG RBD Domain - GMT ratio2.22.02.0
Week 12 (Day 85) - Response antibody titers IgG S Protein - GMT ratio0.30.20.2
Week 26 (Day 182) - Response neutralizing antibody titers - GMT ratio2.41.01.6
Week 26 (Day 182) - Response antibody titers IgG RBD Domain - GMT ratio1.51.21.4
Week 26 (Day 182) - Response antibody titers IgG S Protein - GMT ratio0.20.20.2
SecondaryNeutralizing Antibody Titers (Reference Strain) Derived From SARS-CoV-2

For Group B transplant subjects, assessed at baseline (Day 1 of Dose 1) and then Day 8, Weeks 4, 12, and 26 post Dose 1, and at Dose 2 (Day 1) and the Day 8, Weeks 4, 12, and 26 post Dose 2. Because the 11 participants of the arm 'Group B Immunology Subset Transplant Participants' are the same 11 participants of the arm 'Group B Immunology Subset Transplant Participants', data is not presented for this arm to avoid duplication of data.

Time frame:
From baseline (Day 1 of Dose 1) up to 26 weeks after Dose 2
Reported as:
Geometric mean · Titer
Neutralizing Antibody Titers (Reference Strain) Derived From SARS-CoV-2
TiterGroup B Transplant Participants
Day 1 of Dose 1NA (NA to NA)
Day 8 of Dose 148.3 (13.0 to 179.2)
Week 4 (Day 29) of Dose 1124.4 (25.4 to 609.6)
Week 12 (Day 85) of Dose 180.0 (17.1 to 374.8)
Week 26 (Day 182) of Dose 1108.9 (23.1 to 513.0)
Day 1 pre Dose 247.6 (7.3 to 311.5)
Day 8 post Dose 2142.5 (9.4 to 2160.6)
Week 4 (Day 29) post Dose 2452.5 (61.7 to 3317.6)
Week 12 (Day 85) post Dose 2142.5 (21.5 to 945.6)
Week 26 (Day 182) post Dose 2127.0 (19.7 to 819.1)
SecondaryAntibody Titers (ELISA) (Reference Strain) to Recombinant S1 and RBD Protein Derived From SARS-CoV-2

For Group B transplant subjects, assessed at baseline (Day 1 of Dose 1) and then Day 8, Weeks 4, 12, and 26 post Dose 1, and at Dose 2 (Day 1) and the Day 8, Weeks 4, 12, and 26 post Dose 2. Because the 11 participants of the arm 'Group B Immunology Subset Transplant Participants' are the same 11 participants of the arm 'Group B Immunology Subset Transplant Participants', data is not presented for this arm to avoid duplication of data.

Time frame:
From baseline (Day 1 of Dose 1) up to 26 weeks after Dose 2
Reported as:
Geometric mean · Titer
Antibody Titers (ELISA) (Reference Strain) to Recombinant S1 and RBD Protein Derived From SARS-CoV-2
TiterGroup B Transplant Participants
Response antibody titers IgG RBD Domain reference strain (ELISA) - Baseline (Day 1 of Dose 1)730.5 (157.1 to 3397.0)
Response antibody titers IgG S Protein reference strain (ELISA) - Baseline (Day 1 of Dose 1)599.1 (117.1 to 3064.9)
Response antibody titers IgG RBD Domain reference strain (ELISA) - Day 8 of Dose 14328.8 (512.9 to 36532.1)
Response antibody titers IgG S Protein reference strain (ELISA) - Day 8 of Dose 15078.0 (528.0 to 48838.3)
Response antibody titers IgG RBD Domain reference strain (ELISA) - Week 4 (Day 29) of Dose 16616.9 (987.7 to 44327.3)
Response antibody titers IgG S Protein reference strain (ELISA) - Week 4 (Day 29) of Dose 17937.6 (1179.2 to 53431.0)
Response antibody titers IgG RBD Domain reference strain (ELISA)- Week 12 (Day 85) of Dose 15065.9 (791.0 to 32443.1)
Response antibody titers IgG S Protein reference strain (ELISA) - Week 12 (Day 85) of Dose 111988.6 (1607.4 to 89413.3)
Response antibody titers IgG RBD Domain reference strain (ELISA) - Week 26 (Day 182) of Dose 110602.6 (2076.7 to 54130.4)
Response antibody titers IgG S Protein reference strain (ELISA) - Week 26 (Day 182) of Dose 119644.7 (5085.2 to 75890.1)
Response antibody titers IgG RBD Domain reference strain (ELISA) - Day 1 pre Dose 23633.0 (506.1 to 26078.1)
Response antibody titers IgG S Protein reference strain (ELISA) - Day 1 pre Dose 25822.9 (894.5 to 37904.8)
Response antibody titers IgG RBD Domain reference strain (ELISA) - Day 8 post Dose 212441.7 (1398.3 to 110702.9)
Response antibody titers IgG S Protein reference strain (ELISA) - Day 8 post Dose 222067.6 (2752.2 to 176945.0)
Response antibody titers IgG RBD Domain reference strain (ELISA) - Week 4 (Day 29) post Dose 213625.0 (2884.8 to 64350.9)
Response antibody titers IgG S Protein reference strain (ELISA) - Week 4 (Day 29) post Dose 234242.9 (7476.0 to 156845.8)
Response antibody titers IgG RBD Domain reference strain (ELISA) - Week 12 (Day 85) post Dose 212265.4 (1706.1 to 88179.1)
Response antibody titers IgG S Protein reference strain (ELISA) - Week 12 (Day 85) post Dose 224015.7 (3852.9 to 149692.4)
Response antibody titers IgG RBD Domain reference strain (ELISA) - Week 26 (Day 182) post Dose 213468.1 (2320.5 to 78167.7)
Response antibody titers IgG S Protein reference strain (ELISA) - Week 26 (Day 182) post Dose 210833.5 (1763.7 to 66543.9)

Adverse events

Collected over Local reactions/systemic events: within 7 days after each IMP dose; SAEs: from Day 1 (Dose 1) up to Day 182 after Dose 2 (approximately 26 weeks after Dose 2); Other AEs in participants with Dose 2 (Group B): All AEs from Day 1 up to Day 50 and in addition if assessed as IMP-related from Day 50 up to Day 182 after Dose 2; Other AEs in participants without Dose 2 (Group A): All AEs from Day 1 up to Day 29 and in addition if assessed as IMP-related from Day 29 up to Day 182.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Group A Comirnaty0/21 (0%)0/21 (0%)3/21 (14.3%)
Group A BNT162b2s010/44 (0%)2/44 (4.5%)7/44 (15.9%)
Group A Total0/65 (0%)2/65 (3.1%)10/65 (15.4%)
Group B Non-transplant Participants0/61 (0%)1/61 (1.6%)4/61 (6.6%)
Group B Transplant Participants0/11 (0%)4/11 (36.4%)7/11 (63.6%)
Group B Total0/72 (0%)5/72 (6.9%)11/72 (15.3%)
Group B Immunology Subset Non-transplant Participants0/22 (0%)0/22 (0%)4/22 (18.2%)
Group B Immunology Subset Transplant Participants0/11 (0%)4/11 (36.4%)7/11 (63.6%)
Group B Immunology Subset Total0/33 (0%)4/33 (12.1%)11/33 (33.3%)
Most frequent serious events
Most frequent serious events
EventGroup A ComirnatyGroup A BNT162b2s01Group A TotalGroup B Non-transplant ParticipantsGroup B Transplant ParticipantsGroup B TotalGroup B Immunology Subset Non-transplant ParticipantsGroup B Immunology Subset Transplant ParticipantsGroup B Immunology Subset Total
Hepatitis EInfections and infestations0/210/440/650/611/111/720/221/111/33
Urinary tract infectionInfections and infestations0/210/440/650/611/111/720/221/111/33
Shunt blood flow excessiveInjury, poisoning and procedural complications0/210/440/650/611/111/720/221/111/33
Basal cell carcinomaNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/210/440/650/611/111/720/221/111/33
Supraventricular tachycardiaCardiac disorders0/211/441/650/610/110/720/220/110/33
Hypertensive crisisVascular disorders0/211/441/650/610/110/720/220/110/33
Chronic sinusitisInfections and infestations0/210/440/651/610/111/720/220/110/33
Most frequent other events
Most frequent other events
EventGroup A ComirnatyGroup A BNT162b2s01Group A TotalGroup B Non-transplant ParticipantsGroup B Transplant ParticipantsGroup B TotalGroup B Immunology Subset Non-transplant ParticipantsGroup B Immunology Subset Transplant ParticipantsGroup B Immunology Subset Total
NasopharyngitisInfections and infestations1/213/444/651/613/114/721/223/114/33
ArthralgiaMusculoskeletal and connective tissue disorders2/211/443/650/610/110/720/220/110/33
NauseaGastrointestinal disorders0/210/440/650/611/111/720/221/111/33
FatigueGeneral disorders0/212/442/651/611/112/721/221/112/33
PyrexiaGeneral disorders0/210/440/650/611/111/720/221/111/33
Urinary tract infectionInfections and infestations0/210/440/650/611/111/720/221/111/33
Back painMusculoskeletal and connective tissue disorders0/210/440/650/611/111/720/221/111/33
Muscle tightnessMusculoskeletal and connective tissue disorders0/210/440/650/611/111/720/221/111/33
Musculoskeletal chest painMusculoskeletal and connective tissue disorders0/210/440/650/611/111/720/221/111/33
HeadacheNervous system disorders0/211/441/652/610/112/722/220/112/33

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)Group A ComirnatyGroup A BNT162b2s01Group B Non-transplant ParticipantsGroup B Transplant ParticipantsTotal
<=18 years00000
Between 18 and 65 years17285011106
>=65 years41611031
Age, Continuous
Age, Continuous(years)Group A ComirnatyGroup A BNT162b2s01Group B Non-transplant ParticipantsGroup B Transplant ParticipantsTotal
Group A53.91 ± 15.1355.81 ± 15.20——55.19 ± 15.09
Group B——49.17 ± 16.7250.88 ± 11.9249.43 ± 16.02
Sex: Female, Male
Sex: Female, Male(Participants)Group A ComirnatyGroup A BNT162b2s01Group B Non-transplant ParticipantsGroup B Transplant ParticipantsTotal
Female92029563
Male122432674
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Group A ComirnatyGroup A BNT162b2s01Group B Non-transplant ParticipantsGroup B Transplant ParticipantsTotal
Hispanic or Latino10001
Not Hispanic or Latino20446111136
Unknown or Not Reported00000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Group A ComirnatyGroup A BNT162b2s01Group B Non-transplant ParticipantsGroup B Transplant ParticipantsTotal
American Indian or Alaska Native00000
Asian01001
Native Hawaiian or Other Pacific Islander00000
Black or African American01001
White21426111135
More than one race00000
Unknown or Not Reported00000
Region of Enrollment
Region of Enrollment(Participants)Group A ComirnatyGroup A BNT162b2s01Group B Non-transplant ParticipantsGroup B Transplant ParticipantsTotal
Germany21446111137
Weight
Weight(kg)Group A ComirnatyGroup A BNT162b2s01Group B Non-transplant ParticipantsGroup B Transplant ParticipantsTotal
Group A76.76 ± 10.8076.73 ± 13.45——76.74 ± 12.57
Group B——76.79 ± 13.8674.14 ± 10.9376.38 ± 13.42
08

Study locations

4 sites
  • CRS Clinical Research Services Berlin GmbH
    Berlin, 13353, Germany
  • University Hospital Frankfurt, Infectiology
    Frankfurt, 60590, Germany
  • University Hospital Heidelberg, Clinical Pharmacology
    Heidelberg, 69117, Germany
  • CRS Clinical Research Services Mannheim GmbH
    Mannheim, 68167, Germany
09

References and documents

Publications

  • Quandt J, Muik A, Salisch N, Lui BG, Lutz S, Kruger K, Wallisch AK, Adams-Quack P, Bacher M, Finlayson A, Ozhelvaci O, Vogler I, Grikscheit K, Hoehl S, Goetsch U, Ciesek S, Tureci O, Sahin U. Omicron BA.1 breakthrough infection drives cross-variant neutralization and memory B cell formation against conserved epitopes. Sci Immunol. 2022 Sep 16;7(75):eabq2427. doi: 10.1126/sciimmunol.abq2427. Epub 2022 Sep 16. PubMed 35653438 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jul 2021 to primary completion in Apr 2022, 8 months.

Results were first posted in Sep 2024, 2 years 5 months after primary completion.

Of 224 industry-sponsored phase 2 interventional studies under COVID-19, half reached primary completion within 8 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 13. This study's 8 months is close to that.

Counting every sponsor, half of 583 studies reached it within 9 months; a quarter within 5 and three quarters within 16.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 25, 2021
First posted
Jul 2, 2021
StartActual
Jul 26, 2021
Primary completionActual
Apr 14, 2022
CompletionActual
Sep 16, 2022
Results first posted
Sep 19, 2024
Last update
Sep 19, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 19, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04949490
Lead sponsor
BioNTech SE
Responsible party
Sponsor
First posted
Jul 2, 2021
Start date
Jul 26, 2021
Primary completion
Apr 14, 2022
Completion
Sep 16, 2022
Results posted
Sep 19, 2024
Last update
Sep 19, 2024

Study contacts

BioNTech Responsible Person
study director · BioNTech SE

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: BNT162 Vaccine

Start the discussion